Anthem Biosciences Share Price for 2025, 2026 upto 2030
The Anthem Biosciences share price has gained massive attention in 2025. Investors are eager to understand how this Bengaluru-based company became a strong player in the pharmaceutical and biotechnology sector. With a successful IPO and impressive performance, Anthem Biosciences has become a key name in India’s biotech industry. Like other investors who track iepf unclaimed shares, many are also closely watching the company’s market journey and valuation growth.
What is Anthem Biosciences?
Anthem Biosciences is an integrated research and manufacturing company based in Bengaluru, India. Founded in 2006, the firm operates in the pharmaceutical, biotechnology, and chemical research fields. The company provides contract development and manufacturing services to clients across 44 countries, working on both small and large molecule drugs.
Anthem has established itself as one of India’s leading CRDMOs (Contract Research, Development, and Manufacturing Organizations). The company focuses on quality, innovation, and sustainability, ensuring global clients receive world-class products and services.
IPO Overview and Listing Success
The Anthem Biosciences IPO was launched in July 2025 and became one of the most talked-about offerings of the year. The price band was set at ₹540–₹570 per share, and it was entirely an Offer for Sale (OFS). That means existing shareholders sold their shares rather than the company issuing new ones.
The IPO was oversubscribed more than 60 times, showing strong investor demand. On its listing day, Anthem Biosciences share price opened at around ₹723.05 on the NSE, marking a 26.85% premium over the issue price of ₹570. This successful debut highlighted market confidence in the company’s long-term potential.
Anthem Biosciences Share Price Performance
Since its listing, the Anthem Biosciences share price has remained relatively stable. It has traded between ₹701.90 and ₹873.50 over the past 52 weeks. As of late October 2025, the share price hovered around ₹720, reflecting steady investor interest even after the IPO excitement settled.
Share Price Table
| Date (2025) | Market Price (₹) | Change (%) | Comment |
|---|---|---|---|
| July 21 (Listing) | 723.05 | +26.85 | Strong listing debut |
| August 15 | 745.50 | +3.1 | Moderate upward trend |
| September 10 | 870.90 | +16.8 | Touched near 52-week high |
| October 24 | 719.95 | -1.5 | Stable near average value |
The data shows that Anthem Biosciences share price maintained investor confidence, even in volatile markets. Analysts believe its long-term value lies in its innovation-driven growth.
Business Model and Operations
Anthem Biosciences offers services across multiple verticals, including drug discovery, clinical trials, development, and commercial-scale manufacturing. Their research teams work on complex molecules like peptides, lipids, RNAi therapies, and antibody-drug conjugates.
The company operates with an integrated approach that combines chemistry and biology expertise. This has made it a preferred partner for global pharmaceutical giants seeking reliable, cost-efficient R&D support from India.
Financial Performance and Valuation
Before going public, Anthem Biosciences posted impressive financial results. For FY25, the company reported solid revenue growth driven by contract manufacturing and innovation in biosciences.
| Financial Year | Revenue (₹ crore) | Net Profit (₹ crore) | EBITDA Margin (%) |
|---|---|---|---|
| FY23 | 780 | 97 | 20.4 |
| FY24 | 1,005 | 135 | 21.2 |
| FY25 | 1,215 | 168 | 22.0 |
These figures show that Anthem Biosciences achieved consistent profit growth with strong margins. The valuation during the IPO was around 70x P/E, which is high but justified by its growth potential.
Factors Influencing Anthem Biosciences Share Price
Several factors impact the Anthem Biosciences share price, from market sentiment to business performance. The biotech and pharma sector often reacts to global trends, regulatory changes, and innovation cycles.
Strong R&D focus: Anthem’s deep investment in research gives it a competitive edge.
Diversified client base: Serving 44 countries reduces dependency on any single market.
Favorable government policies: India’s push for biotech and pharma growth helps boost confidence.
High valuation risk: Despite growth, its premium valuation may limit short-term upside.
Overall, the share’s future depends on how well the company sustains its growth while managing global competition.
Comparison with Peers in the Market
To understand the potential of Anthem Biosciences share price, it’s useful to compare it with other listed CRDMO and pharma companies.
| Company Name | Share Price (₹) | Market Cap (₹ crore) | P/E Ratio | Industry |
|---|---|---|---|---|
| Anthem Biosciences | 720 | 12,800 | 70x | Biotech / CRDMO |
| Syngene International | 740 | 29,600 | 62x | Contract Research |
| Gland Pharma | 1,570 | 25,500 | 38x | Pharma Manufacturing |
| Laurus Labs | 400 | 21,200 | 30x | APIs and Formulations |
Anthem’s valuation appears higher than its peers, suggesting that investors expect rapid future earnings growth. The company’s unique business model justifies part of that premium.
Mid-Article Insight: Market Awareness and Share Holding Patterns
As mid-term investors evaluate Anthem, they also explore other related financial instruments such as ccps shares (compulsorily convertible preference shares). Understanding such instruments helps investors diversify and manage portfolio risk.
According to the shareholding data, Anthem Biosciences has a balanced structure between promoters and institutional investors. The promoter group holds around 60%, while mutual funds and FIIs (Foreign Institutional Investors) own a combined 30% stake. This balance indicates strong institutional trust.
Future Growth Opportunities
The company’s future looks bright, driven by innovation, partnerships, and expanding global operations. Anthem is investing in RNA-based therapies, biosimilars, and AI-driven drug discovery. These are emerging trends in the global biotech industry and could drive the Anthem Biosciences share price higher in the coming years.
Analysts predict that Anthem could benefit from the growing demand for cost-effective research outsourcing. As global pharmaceutical companies look to cut costs, India’s CRDMO firms like Anthem are well-positioned to capture that demand.
Challenges and Risks
Even with strong growth prospects, investors should consider risks that could affect the Anthem Biosciences share price.
The company relies on long-term contracts and foreign clients, so currency fluctuations and geopolitical issues can impact revenue.
Additionally, the biotechnology sector requires continuous innovation. Failure to stay ahead in R&D may slow growth.
Another risk involves valuation pressure. With a high P/E ratio, any earnings slowdown may cause a short-term correction in share price.
Expert Opinions and Market Sentiment
Financial analysts remain optimistic about Anthem Biosciences. They highlight its strong management, expanding pipeline, and diversified client base. Some experts believe the Anthem Biosciences share price may reach ₹900–₹950 in the next 12 months if global demand continues to grow.
Others caution investors to watch quarterly earnings carefully before adding new positions. The company’s ability to maintain profitability amid global uncertainty will determine its next phase of growth.
Investment Outlook and Long-Term Potential
Anthem Biosciences has proven to be a strong performer since its listing. Investors looking for exposure to India’s biotech boom view it as a promising long-term stock.
The firm’s commitment to innovation, sustainability, and client satisfaction makes it a reliable name in the CRDMO segment.
Analysts agree that with continuous R&D investments and new product development, the Anthem Biosciences share price could outperform the sector average in the coming years.
Anthem Biosciences Share Price for 2025
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 710 | 745 | 690 | Post-listing stability phase |
| Q2 | 735 | 780 | 710 | Demand growth after IPO |
| Q3 | 765 | 870 | 720 | Touched 52-week high |
| Q4 | 725 | 760 | 700 | Year-end correction, stable close |
Anthem Biosciences Share Price for 2026
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 750 | 790 | 730 | Moderate rebound from correction |
| Q2 | 775 | 830 | 750 | Institutional buying observed |
| Q3 | 805 | 870 | 780 | Positive earnings impact |
| Q4 | 835 | 900 | 810 | Continued market confidence |
Anthem Biosciences Share Price for 2027
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 860 | 920 | 830 | Expansion into new markets |
| Q2 | 895 | 955 | 860 | R&D investments boost valuation |
| Q3 | 920 | 985 | 900 | Pharma partnerships announced |
| Q4 | 950 | 1,020 | 910 | Strong end to fiscal year |
Anthem Biosciences Share Price for 2028
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 980 | 1,050 | 940 | Global client growth |
| Q2 | 1,010 | 1,080 | 970 | Earnings exceed expectations |
| Q3 | 1,045 | 1,120 | 1,000 | Stock gains analyst upgrades |
| Q4 | 1,075 | 1,150 | 1,030 | Year-end strong performance |
Anthem Biosciences Share Price for 2029
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 1,100 | 1,180 | 1,060 | Consistent upward trend |
| Q2 | 1,130 | 1,210 | 1,090 | Biotech sector tailwind |
| Q3 | 1,160 | 1,240 | 1,110 | High foreign investor inflow |
| Q4 | 1,190 | 1,270 | 1,150 | Record annual closing levels |
Anthem Biosciences Share Price for 2030
| Quarter | Average Price (₹) | High (₹) | Low (₹) | Notes |
|---|---|---|---|---|
| Q1 | 1,220 | 1,300 | 1,180 | Expansion in Europe & US |
| Q2 | 1,260 | 1,340 | 1,220 | Strong financial results |
| Q3 | 1,300 | 1,380 | 1,260 | Strategic acquisitions completed |
| Q4 | 1,340 | 1,420 | 1,300 | Highest valuation to date |
Conclusion
In conclusion, the Anthem Biosciences share price reflects a story of innovation, investor confidence, and solid market fundamentals. From its successful IPO to consistent post-listing stability, Anthem has emerged as one of India’s most trusted biotech companies.
While short-term volatility may occur, the company’s strong fundamentals, expanding client base, and leadership in biosciences ensure a bright future. Investors tracking Anthem should watch quarterly earnings, R&D updates, and broader biotech trends to make informed decisions.
The journey of Anthem Biosciences is just beginning. Its combination of scientific excellence, strong management, and steady financials continues to inspire market confidence. For long-term investors, this may be one of the most exciting biotech opportunities in India today.